top of page

Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.

Lim YJ, Ward V, Brown A, Phillips E, Kronsteiner B, Malone T, Jennings D, Healy S, Longet S, James T, Thomson P, Farrell L, Oates M, Jackson R, Morrison A, Burns M, Carroll M, Klenerman P, Turtle L, Naisbitt D, Rhodes M, Robinson K, Gatto S, Young M, Linton K, Eyre TA, Eyre DW, Dunachie S, Barnes E, Pettitt A.Br J Haematol. 2024 Jun 13. 

Serological evidence of zoonotic filovirus exposure among bushmeat hunters in Guinea.

Akoi Boré J, Timothy JWS, Tipton T, Kekoura I, Hall Y, Hood G, Longet S, Fornace K, Lucien MS, Fehling SK, Koivogui BK, Coggins SA, Laing ED, Broder CC, Magassouba NF, Strecker T, Rossman J, Konde K, Carroll MW.Nat Commun. 2024 May 16;15(1):4171. 

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.

Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, Snowden JA, Lim SH, Bowden SJ, Billingham L, Richter A, Carroll M, Carr EJ, Beale R, Rea D, Parry H, Pirrie S, Lim Z, Satsangi J, Dunachie SJ, Cook G, Miller P, Basu N, Gilmour A, Hodgkins AM, Evans L, Hughes A, Longet S, Meacham G, Yong KL, A'Hearne MJ, Koh MBC, Burns SO, Orchard K, Paterson C, McIlroy G, Murray SM, Thomson T, Dimitriadis S, Goulston L, Miller S, Keillor V, Prendecki M, Thomas D, Kirkham A, McInnes IB, Kearns P; OCTAVE-DUO investigators.Lancet Rheumatol. 2024 Jun;6(6):e339-e351.

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.

Jackson S, Marshall JL, Mawer A, Lopez-Ramon R, Harris SA, Satti I, Hughes E, Preston-Jones H, Cabrera Puig I, Longet S, Tipton T, Laidlaw S, Doherty RP, Morrison H, Mitchell R, Tanner R, Ateere A, Stylianou E, Wu MS, Fredsgaard-Jones TPW, Breuer J, Rapeport G, Ferreira VM, Gleeson F, Pollard AJ, Carroll M, Catchpole A, Chiu C, McShane H; COV-CHIM01 study team.Lancet Microbe. 2024 Apr 26:S2666-5247(24)00025-9.

Obesity Differs from Diabetes Mellitus in Antibody and T Cell Responses Post COVID-19 Recovery.

Ali M, Longet S, Neale I, Rongkard P, Chowdhury FUH, Hill J, Brown A, Laidlaw S, Tipton T, Hoque A, Hassan N, Hackstein CP, Adele S, Akther HD, Abraham P, Paul S, Rahman MM, Alam MM, Parvin S, Hoque Mollah F, Hoque MM, Moore SC, Biswas SK, Turtle L, de Silva TI, Ogbe A, Frater J, Barnes E, Tomic A, Carroll MW, Klenerman P, Kronsteiner B, Chowdhury FR, Dunachie SJ.Clin Exp Immunol. 2024 Apr 20:uxae030. 

Progress with COVID vaccine development and implementation.

Titball RW, Bernstein DI, Fanget NVJ, Hall RA, Longet S, MacAry PA, Rupp RE, van Gils M, von Messling V, Walker DH, Barrett ADT.NPJ Vaccines. 2024 Apr 1;9(1):69

Gonadal androgens are associated with decreased type I interferon production by plasmacytoid dendritic cells and increased IgG titres to BNT162b2 following co-vaccination with live attenuated influenza vaccine in adolescents.

Sampson OL, Jay C, Adland E, Csala A, Lim N, Ebbrecht SM, Gilligan LC, Taylor AE, George SS, Longet S, Jones LC, Barnes E, Frater J, Klenerman P, Dunachie S, Carrol M, Hawley J, Arlt W, Groll A, Goulder P.Front Immunol. 2024 Feb 28;15:1329805.

Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses.

Sinha D, Yaugel-Novoa M, Waeckel L, Paul S, Longet S.Antiviral Res. 2024 Mar;223:105823.

Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents.

Ratcliffe H, Tiley KS, Longet S, Tonry C, Roarty C, Watson C, Amirthalingam G, Vichos I, Morey E, Douglas NL, Marinou S, Plested E, Aley PK, Galiza E, Faust SN, Hughes S, Murray C, Roderick MR, Shackley F, Oddie S, Lee TWR, Turner DPJ, Raman M, Owens S, Turner PJ, Cockerill H, Lopez Bernal J, Ijaz S, Poh J, Shute J, Linley E, Borrow R, Hoschler K, Brown KE, Carroll MW, Klenerman P, Dunachie SJ, Ramsay M, Voysey M, Waterfield T, Snape MD.iScience. 2023 Nov 21;26(12):108500. 

Characterization of Canine Peyer's Patches by Multidimensional Analysis: Insights from Immunofluorescence, Flow Cytometry, and Single-Cell RNA Sequencing.

Miguelena Chamorro B, Hameed SA, Dechelette M, Claude JB, Piney L, Chapat L, Swaminathan G, Poulet H, Longet S, De Luca K, Mundt E, Paul S.Immunohorizons. 2023 Nov 1;7(11):788-805.

Age- and sex-specific differences in immune responses to BNT162b2 COVID-19 and live-attenuated influenza vaccines in UK adolescents.

Jay C, Adland E, Csala A, Lim N, Longet S, Ogbe A, Ratcliff J, Sampson O, Thompson CP, Turtle L, Barnes E, Dunachie S, Klenerman P, Carroll M, Goulder P.Front Immunol. 2023 Oct 6;14:1248630. 

Pivotal role of tissue-resident memory lymphocytes in the control of mucosal infections: can mucosal vaccination induce protective tissue-resident memory T and B cells?

Longet S, Paul S.Front Immunol. 2023 Sep 11;14:1216402.

Cellular immunity to SARS-CoV-2 following intrafamilial exposure in seronegative family members.

Jay C, Adland E, Csala A, Dold C, Edmans M, Hackstein CP, Jamsen A, Lim N, Longet S, Ogbe A, Sampson O, Skelly D, Spiller OB, Stafford L, Thompson CP, Turtle L, Barnes E, Dunachie S, Carroll M, Klenerman P, Conlon C, Goulder P, Jones LC.Front Immunol. 2023 Aug 29;14:1248658.

CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study.

Neale I, Ali M, Kronsteiner B, Longet S, Abraham P, Deeks AS, Brown A, Moore SC, Stafford L, Dobson SL, Plowright M, Newman TAH, Wu MY; Crick COVID Immunity Pipeline; Carr EJ, Beale R, Otter AD, Hopkins S, Hall V, Tomic A, Payne RP, Barnes E, Richter A, Duncan CJA, Turtle L, de Silva TI, Carroll M, Lambe T, Klenerman P, Dunachie S; PITCH Consortium.mBio. 2023 Sep 1;14(5):e0121223. 

Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history.

Hornsby H,* Nicols AR*, Longet S*, Liu C*, Tomic A, Angyal A, Kronsteiner B, Tyerman JK, Tipton T, Zhang P, Gallis M, Supasa P, Selvaraj M, Abraham P, Neale I, Ali M, Barratt NA, Nell JM, Gustafsson L, Strickland S, Grouneva I, Rostron T, Moore SC, Hering LM, Dobson SL, Bibi S, Mongkolsapaya J, Lambe T, Wootton D, Hall V, Hopkins S, Dong T, Barnes E, Screaton G; PITCH Consortium; Richter A, Turtle L, Rowland-Jones SL, Carroll M, Duncan CJA, Klenerman P, Dunachie SJ, Payne RP, de Silva TI.Nat Commun. 2023 Aug 21;14(1):5065.

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.

Barnes E, Goodyear CS, Willicombe M, Gaskell C, Siebert S, I de Silva T, Murray SM, Rea D, Snowden JA, Carroll M, Pirrie S, Bowden SJ, Dunachie SJ, Richter A, Lim Z, Satsangi J, Cook G, Pope A, Hughes A, Harrison M, Lim SH, Miller P, Klenerman P; PITCH consortium; Basu N, Gilmour A, Irwin S, Meacham G, Marjot T, Dimitriadis S, Kelleher P, Prendecki M, Clarke C, Mortimer P, McIntyre S, Selby R, Meardon N, Nguyen D, Tipton T, Longet S, Laidlaw S, Orchard K, Ireland G; CONSENSUS; Thomas D, Kearns P, Kirkham A, McInnes IB; OCTAVE Collaborative Group.Nat Med. 2023 Jul 6. 

Bordetella bronchiseptica and Bordetella pertussis: Similarities and Differences in Infection, Immuno-Modulation, and Vaccine Considerations.

Miguelena Chamorro B, De Luca K, Swaminathan G, Longet S, Mundt E, Paul S.Clin Microbiol Rev. 2023 Jun 12:e0016422. 

Prior COVID-19 Immunization Does Not Cause IgA- or IgG-Dependent Enhancement of SARS-CoV-2 Infection.

Yaugel-Novoa M, Noailly B, Jospin F, Berger AE, Waeckel L, Botelho-Nevers E, Longet S, Bourlet T, Paul S.Vaccines (Basel). 2023 Mar 31;11(4):773. 

 

Pre-clinical models to define correlates of protection for SARS-CoV-2.

Brady C, Tipton T, Longet S, Carroll MW.Front Immunol. 2023 Mar 30;14:1166664.

 

Association of IFNAR1 and IFNAR2 with COVID-19 severity.

Yaugel-Novoa M, Bourlet T, Longet S, Botelho-Nevers E, Paul S.Lancet Microbe. 2023 Jul;4(7):e487.

Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.

Dijokaite-Guraliuc A, Das R, Zhou D, Ginn HM, Liu C, Duyvesteyn HME, Huo J, Nutalai R, Supasa P, Selvaraj M, de Silva TI, Plowright M, Newman TAH, Hornsby H, Mentzer AJ, Skelly D, Ritter TG, Temperton N, Klenerman P, Barnes E, Dunachie SJ; OPTIC consortium; Roemer C, Peacock TP, Paterson NG, Williams MA, Hall DR, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR.Cell Rep. 2023 Mar 7;42(4):112271. doi: 10.1016/j.celrep.2023.112271.

Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.

Moore SC*, Kronsteiner B*, Longet S*, Adele S*, Deeks AS, Liu C, Dejnirattisai W, Reyes LS, Meardon N, Faustini S, Al-Taei S, Tipton T, Hering LM, Angyal A, Brown R, Nicols AR, Dobson SL, Supasa P, Tuekprakhon A, Cross A, Tyerman JK, Hornsby H, Grouneva I, Plowright M, Zhang P, Newman TAH, Nell JM, Abraham P, Ali M, Malone T, Neale I, Phillips E, Wilson JD, Murray SM, Zewdie M, Shields A, Horner EC, Booth LH, Stafford L, Bibi S, Wootton DG, Mentzer AJ, Conlon CP, Jeffery K, Matthews PC, Pollard AJ, Brown A, Rowland-Jones SL, Mongkolsapaya J, Payne RP, Dold C, Lambe T, Thaventhiran JED, Screaton G, Barnes E, Hopkins S, Hall V, Duncan CJA, Richter A, Carroll M, de Silva TI, Klenerman P, Dunachie S, Turtle L; PITCH Consortium.Med (N Y). 2023 Mar 10;4(3):191-215.e9. doi: 10.1016/j.medj.2023.02.004.

Evaluation of QuantiFERON SARS-CoV-2 interferon- release assay following SARS-CoV-2 infection and vaccination.

Johnson SA, Phillips E, Adele S, Longet S, Malone T, Mason C, Stafford L, Jamsen A, Gardiner S, Deeks A, Neo J, Blurton EJ, White J, Ali M, Kronsteiner B, Wilson JD, Skelly DT, Jeffery K, Conlon CP, Goulder P; PITCH Consortium; Carroll M, Barnes E, Klenerman P, Dunachie SJ.Clin Exp Immunol. 2023 Feb 21:uxad027. doi: 10.1093/cei/uxad027.

Influence of Landscape Patterns on Exposure to Lassa Fever Virus, Guinea.

Longet S, Leggio C, Bore JA, Key S, Tipton T, Hall Y, Koundouno FR, Bower H, Bhattacharyya T, Magassouba N, Günther S, Henao-Restrapo AM, Rossman JS, Konde MK, Fornace K, Carroll MW.

Emerg Infect Dis. 2023 Feb;29(2):304-313. doi: 10.3201/eid2902.212525.

Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV.

Fidler S, Fox J, Tipoe T, Longet S, Tipton T, Abeywickrema M, Adele S, Alagaratnam J, Ali M, Aley PK, Aslam S, Balasubramanian A, Bara A, Bawa T, Brown A, Brown H, Cappuccini F, Davies S, Fowler J, Godfrey L, Goodman AL, Hilario K, Hackstein CP, Mathew M, Mujadidi YF, Packham A, Petersen C, Plested E, Pollock KM, Ramasamy MN, Robinson H, Robinson N, Rongkard P, Sanders H, Serafimova T, Spence N, Waters A, Woods D, Zacharopoulou P, Barnes E, Dunachie S, Goulder P, Klenerman P, Winston A, Hill AVS, Gilbert SC, Carroll M, Pollard AJ, Lambe T, Ogbe A, Frater J.Clin Infect Dis. 2022 Oct 5:ciac796. doi: 10.1093/cid/ciac796. Online ahead of print.

 

mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.

Longet S, Hargreaves A, Healy S, Brown R, Hornsby HR, Meardon N, Tipton T, Barnes E, Dunachie S, Duncan CJA, Klenerman P, Richter A, Turtle L, de Silva TI, Carroll MW.Front Immunol. 2022 Sep 8;13:953949. doi: 10.3389/fimmu.2022.953949. 

Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and Pathogenesis.

Mellors J, Tipton T, Fehling SK, Akoi Bore J, Koundouno FR, Hall Y, Hudson J, Alexander F, Longet S, Taylor S, Gorringe A, Magassouba N, Konde MK, Hiscox J, Strecker T, Carroll M.Front Immunol. 2022 Apr 12;13:857481. doi: 10.3389/fimmu.2022.857481.

SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients.

Shankar S, Beckett J, Tipton T, Ogbe A, Kasanyinga M, Dold C, Lumley S, Dengu F, Rompianesi G, Elgilani F, Longet S, Deeks A, Payne RP, Duncan CJA, Richter A, de Silva TI, Turtle L, Bull K, Barnardo M, Friend PJ, Dunachie SJ, Hester J, Issa F, Barnes E, Carroll MW, Klenerman P.J Am Soc Nephrol. 2022 May;33(5):883-887. doi: 10.1681/ASN.2021121587. 

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Tomic A, Skelly DT, Ogbe A, O'Connor D, Pace M, Adland E, Alexander F, Ali M, Allott K, Azim Ansari M, Belij-Rammerstorfer S, Bibi S, Blackwell L, Brown A, Brown H, Cavell B, Clutterbuck EA, de Silva T, Eyre D, Lumley S, Flaxman A, Grist J, Hackstein CP, Halkerston R, Harding AC, Hill J, James T, Jay C, Johnson SA, Kronsteiner B, Lie Y, Linder A, Longet S, Marinou S, Matthews PC, Mellors J, Petropoulos C, Rongkard P, Sedik C, Silva-Reyes L, Smith H, Stockdale L, Taylor S, Thomas S, Tipoe T, Turtle L, Vieira VA, Wrin T; OPTIC Clinical Group; PITCH Study Group; C-MORE Group, Pollard AJ, Lambe T, Conlon CP, Jeffery K, Travis S, Goulder P, Frater J, Mentzer AJ, Stafford L, Carroll MW, James WS, Klenerman P, Barnes E, Dold C, Dunachie SJ.Nat Commun. 2022 Mar 10;13(1):1251. doi: 10.1038/s41467-022-28898-1.

Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques.

White AD, Sibley L, Sarfas C, Morrison AL, Bewley K, Churchward C, Fotheringham S, Gkolfinos K, Gooch K, Handley A, Humphries HE, Hunter L, Kennard C, Longet S, Mabbutt A, Moffatt M, Rayner E, Tipton T, Watson R, Hall Y, Bodman-Smith M, Gleeson F, Dennis M, Salguero FJ, Carroll M, McShane H, Cookson W, Hopkin J, Sharpe S.Front Immunol. 2022 Feb 9;12:801799. doi: 10.3389/fimmu.2021.801799.

 

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Ogbe A, Pace M, Bittaye M, Tipoe T, Adele S, Alagaratnam J, Aley PK, Ansari MA, Bara A, Broadhead S, Brown A, Brown H, Cappuccini F, Cinardo P, Dejnirattisai W, Ewer KJ, Fok H, Folegatti PM, Fowler J, Godfrey L, Goodman AL, Jackson B, Jenkin D, Jones M, Longet S, Makinson RA, Marchevsky NG, Mathew M, Mazzella A, Mujadidi YF, Parolini L, Petersen C, Plested E, Pollock KM, Rajeswaran T, Ramasamy MN, Rhead S, Robinson H, Robinson N, Sanders H, Serrano S, Tipton T, Waters A, Zacharopoulou P, Barnes E, Dunachie S, Goulder P, Klenerman P, Screaton GR, Winston A, Hill AV, Gilbert SC, Carroll M, Pollard AJ, Fidler S, Fox J, Lambe T, Frater J.JCI Insight. 2022 Apr 8;7(7):e157031. doi: 10.1172/jci.insight.157031.

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study.

Angyal A*, Longet S*, Moore SC*, Payne RP*, Harding A, Tipton T, Rongkard P, Ali M, Hering LM, Meardon N, Austin J, Brown R, Skelly D, Gillson N, Dobson SL, Cross A, Sandhar G, Kilby JA, Tyerman JK, Nicols AR, Spegarova JS, Mehta H, Hornsby H, Whitham R, Conlon CP, Jeffery K, Goulder P, Frater J, Dold C, Pace M, Ogbe A, Brown H, Ansari MA, Adland E, Brown A, Chand M, Shields A, Matthews PC, Hopkins S, Hall V, James W, Rowland-Jones SL, Klenerman P, Dunachie S, Richter A, Duncan CJA, Barnes E, Carroll M, Turtle L, de Silva TI; PITCH Consortium.

Lancet Microbe. 2021 Nov 9. doi: 10.1016/S2666-5247(21)00275-5. doi: 10.1016/S2666-5247(21)00275-5.

 

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.

Payne RP*, Longet S*, Austin JA*, Skelly DT*, Dejnirattisai W, Adele S, Meardon N, Faustini S, Al-Taei S, Moore SC, Tipton T, Hering LM, Angyal A, Brown R, Nicols AR, Gillson N, Dobson SL, Amini A, Supasa P, Cross A, Bridges-Webb A, Reyes LS, Linder A, Sandhar G, Kilby JA, Tyerman JK, Altmann T, Hornsby H, Whitham R, Phillips E, Malone T, Hargreaves A, Shields A, Saei A, Foulkes S, Stafford L, Johnson S, Wootton DG, Conlon CP, Jeffery K, Matthews PC, Frater J, Deeks AS, Pollard AJ, Brown A, Rowland-Jones SL, Mongkolsapaya J, Barnes E, Hopkins S, Hall V, Dold C, Duncan CJA, Richter A, Carroll M, Screaton G, de Silva TI, Turtle L, Klenerman P, Dunachie S; PITCH Consortium.

Cell. 2021 Nov 11;184(23):5699-5714.e11. doi: 10.1016/j.cell.2021.10.011. 

Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application.

Hargreaves A, Brady C, Mellors J, Tipton T, Carroll MW, Longet S.

Pathogens. 2021 Sep 16;10(9):1201.

 

Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques.

Bewley KR, Gooch K, Thomas KM, Longet S, Wiblin N, Hunter L, Chan K, Brown P, Russell RA, Ho C, Slack G, Humphries HE, Alden L, Allen L, Aram M, Baker N, Brunt E, Cobb R, Fotheringham S, Harris D, Kennard C, Leung S, Ryan K, Tolley H, Wand N, White A, Sibley L, Sarfas C, Pearson G, Rayner E, Xue X, Lambe T, Charlton S, Gilbert S, Sattentau QJ, Gleeson F, Hall Y, Funnell S, Sharpe S, Salguero FJ, Gorringe A, Carroll M.

Sci Adv. 2021 Sep 10;7(37):eabg7996. doi: 10.1126/sciadv.abg7996

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

Skelly DT, Harding AC, Gilbert-Jaramillo J, Knight ML, Longet S, Brown A, Adele S, Adland E, Brown H; Medawar Laboratory Team, Tipton T, Stafford L, Mentzer AJ, Johnson SA, Amini A; OPTIC (Oxford Protective T cell Immunology for COVID-19) Clinical Group, Tan TK, Schimanski L, Huang KA, Rijal P; PITCH (Protective Immunity T cells in Health Care Worker) Study Group; C-MORE/PHOSP-C Group, Frater J, Goulder P, Conlon CP, Jeffery K, Dold C, Pollard AJ, Sigal A, de Oliveira T, Townsend AR, Klenerman P, Dunachie SJ, Barnes E, Carroll MW, James WS.

Nat Commun. 2021 Aug 17;12(1):5061. doi: 10.1038/s41467-021-25167-5

One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.

Gooch KE, Smith TRF, Salguero FJ, Fotheringham SA, Watson RJ, Dennis MJ, Handley A, Humphries HE, Longet S, Tipton T, Sarfas C, Sibley L, Slack GS, Rayner E, Ryan KA, Schultheis K, Ramos SJ, White A, Charlton S, Sharpe SA, Gleeson F, Humeau LM, Hall Y, Broderick KE, Carroll MW.

Vaccine. 2021 Aug 9;39(34):4885-4894. doi: 10.1016/j.vaccine.2021.06.057.

Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines.

*Albutti A, *Longet S, McEntee CP, Quinn S, Liddicoat A, Rîmniceanu C, Lycke N, Lynch L, Cardell S, Lavelle EC.

Vaccines (Basel). 2021 Jun 8;9(6):619. doi: 10.3390/vaccines9060619.

 

Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection

Longet S, Mellors J, Carroll MW, Tipton T.

Front Immunol. 2021 Feb 19;11:599568. doi: 10.3389/fimmu.2020.599568. 

Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19

Salguero FJ, White AD, Slack GS, Fotheringham SA, Bewley KR, Gooch KE, Longet S, Humphries HE, Watson RJ, Hunter L, Ryan KA, Hall Y, Sibley L, Sarfas C, Allen L, Aram M, Brunt E, Brown P, Buttigieg KR, Cavell BE, Cobb R, Coombes NS, Darby A, Daykin-Pont O, Elmore MJ, Garcia-Dorival I, Gkolfinos K, Godwin KJ, Gouriet J, Halkerston R, Harris DJ, Hender T, Ho CMK, Kennard CL, Knott D, Leung S, Lucas V, Mabbutt A, Morrison AL, Nelson C, Ngabo D, Paterson J, Penn EJ, Pullan S, Taylor I, Tipton T, Thomas S, Tree JA, Turner C, Vamos E, Wand N, Wiblin NR, Charlton S, Dong X, Hallis B, Pearson G, Rayner EL, Nicholson AG, Funnell SG, Hiscox JA, Dennis MJ, Gleeson FV, Sharpe S, Carroll MW.

Nat Commun. 2021 Feb 24;12(1):1260. doi: 10.1038/s41467-021-21389-9.

 

Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013-16 West Africa epidemic

Tipton TRW, Hall Y, Bore JA, White A, Sibley LS, Sarfas C, Yuki Y, Martin M, Longet S, Mellors J, Ewer K, Günther S, Carrington M, Kondé MK, Carroll MW. 

Nat Commun. 2021 Feb 19;12(1):1153. doi: 10.1038/s41467-021-21411-0.

 

Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity

Ryan KA, Bewley KR, Fotheringham SA, Slack GS, Brown P, Hall Y, Wand NI, Marriott AC, Cavell BE, Tree JA, Allen L, Aram MJ, Bean TJ, Brunt E, Buttigieg KR, Carter DP, Cobb R, Coombes NS, Findlay-Wilson SJ, Godwin KJ, Gooch KE, Gouriet J, Halkerston R, Harris DJ, Hender TH, Humphries HE, Hunter L, Ho CMK, Kennard CL, Leung S, Longet S, Ngabo D, Osman KL, Paterson J, Penn EJ, Pullan ST, Rayner E, Skinner O, Steeds K, Taylor I, Tipton T, Thomas S, Turner C, Watson RJ, Wiblin NR, Charlton S, Hallis B, Hiscox JA, Funnell S, Dennis MJ, Whittaker CJ, Catton MG, Druce J, Salguero FJ, Carroll MW. Nat Commun. 2021 Jan 4;12(1):81. doi: 10.1038/s41467-020-20439-y.

 

Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study.

Thom R, Tipton T, Strecker T, Hall Y, Akoi Bore J, Maes P, Raymond Koundouno F, Fehling SK, Krähling V, Steeds K, Varghese A, Bailey G, Matheson M, Coné M, Moussa Keita B, Kouyate S, Richard Ablam A, Laenen L, Vergote V, Guiver M, Timothy J, Atkinson B, Ottowell L, Richards KS, Bosworth A, Longet S, Mellors J, Pannetier D, Duraffour S, Muñoz-Fontela C, Sow O, Koivogui L, Newman E, Becker S, Sprecher A, Raoul H, Hiscox J, Henao-Restrepo AM, Sakoba K, Magassouba N, Günther S, Kader Konde M, Carroll MW.

Lancet Infect Dis. 2020 Oct 13:S1473-3099(20)30736-2. doi: 10.1016/S1473-3099(20)30736-2.

Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics

Mellors J, Tipton T, Longet S, Carroll MW.

Frontiers in Immunology. 2020 July. doi: 10.3389/fimmu.2020.01450

 

Technological Approaches for Improving Vaccination Compliance and Coverage

Lemoine C, Thakur A, Krajišnik D, Guyon R, Longet S, Razim A, Górska S, Pantelić I, Ilić T, Nikolić I, Lavelle EC, Gamian A, Savić S, Milicic A.

Vaccines (Basel). 2020 Jun 16;8(2):304. doi: 10.3390/vaccines8020304.

An oral alpha-galactosylceramide adjuvanted Helicobacter pylori vaccine induces protective IL-1R- and IL-17R-dependent Th1 responses

*Longet S, *Abautret-Daly A, Davitt CJH, McEntee CP, Aversa V, Rosa M, Coulter IS, Holmgren J, Raghavan S, Lavelle EC.

npj Vaccines. 2019 Oct 25. https://doi.org/10.1038/s41541-019-0139-z.

Alpha-Galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines

*Davitt CJH, *Longet S, Albutti A, Aversa V, Nordqvist S, Hackett B, McEntee CP, Rosa M, Coulter IS, Lebens M, Tobias J, Holmgren J and Lavelle EC. Mucosal Immunol. 2019 Jul;12(4):1055-1064. doi: 10.1038/s41385-019-0159-z.

Targeted strategies for mucosal vaccination.

Longet S, Lundahl MLE, Lavelle EC.

Bioconjug Chem. 2018 Jan 4. doi: 10.1021/acs.bioconjchem.7b00738.

Thermostability of the coating, antigen and immunostimulator in an adjuvanted oral capsule vaccine formulation.

Longet S, Aversa V, O'Donnell D, Tobias J, Rosa M, Holmgren J, Coulter IS, Lavelle EC.

Int J Pharm. 2017 Oct 9. pii: S0378-5173(17)30972-9. doi: 10.1016/j.ijpharm.2017.10.013.

A novel adjuvanted capsule based strategy for oral vaccination against infectious diarrhoeal pathogens.

*Davitt CJ, *McNeela EA, *Longet S, Tobias J, Aversa V, McEntee CP, Rosa M, Coulter IS, Holmgren J, Lavelle EC.

J Control Release. 2016 Jul 10;233:162-73. doi: 10.1016/j.jconrel.2016.05.001

Secretory IgA in complex with Lactobacillus rhamnosus potentiates mucosal dendritic cell-mediated Treg cell differentiation via TLR regulatory proteins, RALDH2 and secretion of IL-10 and TGF-β.

Mikulic J, Longet S, Favre L, Benyacoub J, Corthesy B.

Cell Mol Immunol. 2017 Jun;14(6):546-556. doi: 10.1038/cmi.2015.110.

Reconstituted human polyclonal plasma-derived secretory-like IgM and IgA maintain the barrier function of epithelial cells infected with an enteropathogen.

Longet S, Vonarburg C, Lötscher M, Miescher S, Zuercher A, Corthésy B.

J Biol Chem. 2014 Aug 1;289(31):21617-26. doi: 10.1074/jbc.M114.549139.

 

Agglutinating secretory IgA preserves intestinal epithelial cell integrity during apical infection by Shigella flexneri.

Mathias A, Longet S, Corthésy B.

Infect Immun. 2013 Aug;81(8):3027-34. doi: 10.1128/IAI.00303-13.

 

Human plasma-derived polymeric IgA and IgM antibodies associate with secretory component to yield biologically active secretory-like antibodies.

Longet S, Miled S, Lötscher M, Miescher SM, Zuercher AW, Corthésy B.

J Biol Chem. 2013 Feb 8;288(6):4085-94. doi: 10.1074/jbc.M112.410811.

A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection.

Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D.

J Virol. 2011 Dec;85(24):13253-9. doi: 10.1128/JVI.06093-11.

Academic Publications 

PUBLICATIONS

"You always learn more from an experiment that goes wrong than you do from an experiment that goes right" (Sir Harold Kroto, Nobel Prize in Chemistry, 1996)

bottom of page